Parkinson hastalığının klinik seyri ve tedavi seçenekleri
Treatment choices and clinical course of the Parkinson's disease
- Tez No: 49604
- Danışmanlar: PROF. DR. OKAY VURAL
- Tez Türü: Tıpta Uzmanlık
- Konular: Nöroloji, Neurology
- Anahtar Kelimeler: Dopaminerjik ajanlar, Levodopa, Parkinson hastalığı, Selejilin, Dopaminergic agents, Levodopa, Parkinson disease, Selegiline
- Yıl: 1996
- Dil: Türkçe
- Üniversite: Gata
- Enstitü: Tıp Fakültesi
- Ana Bilim Dalı: Nöroloji Ana Bilim Dalı
- Bilim Dalı: Belirtilmemiş.
- Sayfa Sayısı: Belirtilmemiş.
Özet
SUMMARY This study has been done in patients with Parkinson's Disease who applied to GATA Neurology Clinic. 78 patients ( 46 male, 32 female ) whose ages range between 42 and 83 years were included to this study. The patients were followed for 4-24 months ( mean 11.5 months ) and controlled 3-10 times ( mean 5 times ) during the study. 24 patients took Selegiline, 17 monotherapy of Dopamin agonists, 19 Selegiline and Levodopa, 18 combination of Dopamin agonists and Levodopa during the study. We gave Selegiline with the dosage of 10 mg/day to the patients taking only this drug and 1 1 of these patients needed the second Antiparkinsonien drug after a mean period of 7.4 months. Selegiline with the dosage of 10 mg/day and Levodopa with the mean dosage of 328.9 mg/day were given to the patients in group of Selegiline and Levodopa combination. After the dose of Levodopa was regulated an another third drug was added to the therapy in 4 patients ( 21.8 % ) due to aggrevation of symptoms. Pribedil with the mean dosage of 123.5 mg/day was given to the patients in the Dopamin agonists group. A second drug was added to the therapy in 9 patients ( 52.9% ) because of aggrevation of symptoms after 5.7 months. Levodopa ( 343.75 mg/day ) and Dopamine agonists ( Pribedil 135 mg/day, Lisurid 0.45 mg/day, Bromocriptin 36.25 mg/day ) were given to the patients in combination Dopamin agonists and Levodopa. A third drug was added to the patients in this group ( 16.6 % ) after 12.3 months because of aggrevation of symptoms. 48During the study, only 4 patients showed drug side effects. Low frequency of side effects in likely due to follow-up period of short duration. As a result, monothrapy done with Selegiline or Dopamin agonists delay the need of Levodopa in patients with newly diagnosed Parkinson's Disease. A combination Levodopa and Dopamin agonists is the most effective therapy for the patients who have been diagnosed formerly and taken Antiparkinsonien medication. 49
Özet (Çeviri)
SUMMARY This study has been done in patients with Parkinson's Disease who applied to GATA Neurology Clinic. 78 patients ( 46 male, 32 female ) whose ages range between 42 and 83 years were included to this study. The patients were followed for 4-24 months ( mean 11.5 months ) and controlled 3-10 times ( mean 5 times ) during the study. 24 patients took Selegiline, 17 monotherapy of Dopamin agonists, 19 Selegiline and Levodopa, 18 combination of Dopamin agonists and Levodopa during the study. We gave Selegiline with the dosage of 10 mg/day to the patients taking only this drug and 1 1 of these patients needed the second Antiparkinsonien drug after a mean period of 7.4 months. Selegiline with the dosage of 10 mg/day and Levodopa with the mean dosage of 328.9 mg/day were given to the patients in group of Selegiline and Levodopa combination. After the dose of Levodopa was regulated an another third drug was added to the therapy in 4 patients ( 21.8 % ) due to aggrevation of symptoms. Pribedil with the mean dosage of 123.5 mg/day was given to the patients in the Dopamin agonists group. A second drug was added to the therapy in 9 patients ( 52.9% ) because of aggrevation of symptoms after 5.7 months. Levodopa ( 343.75 mg/day ) and Dopamine agonists ( Pribedil 135 mg/day, Lisurid 0.45 mg/day, Bromocriptin 36.25 mg/day ) were given to the patients in combination Dopamin agonists and Levodopa. A third drug was added to the patients in this group ( 16.6 % ) after 12.3 months because of aggrevation of symptoms. 48During the study, only 4 patients showed drug side effects. Low frequency of side effects in likely due to follow-up period of short duration. As a result, monothrapy done with Selegiline or Dopamin agonists delay the need of Levodopa in patients with newly diagnosed Parkinson's Disease. A combination Levodopa and Dopamin agonists is the most effective therapy for the patients who have been diagnosed formerly and taken Antiparkinsonien medication. 49
Benzer Tezler
- Parkinson hastalarında tiroit fonksiyon testleri ve değerlendirilmesi
Thyroid function tests in parkinson disease's patient and evalution
TAMER BAYRAM
- Parkinson hastalığının motor semptomlarının izlenmesine olanak sağlayan giyilebilir PDMonitor® sisteminin derin beyin stimülasyonu uygulanan hastalarda ameliyat öncesi ve sonrası kullanımı
Preoperative and postoperative use of the wearable PDMonitor® system for monitoring motor symptoms in patients with parkinson's disease undergoing deep brain stimulation
HÜSEYİN EMRE DAĞDEVİREN
Tıpta Uzmanlık
Türkçe
2025
Nörolojiİstanbul ÜniversitesiBeyin ve Sinir Cerrahisi Ana Bilim Dalı
PROF. DR. PULAT AKIN SABANCI
- Orta ve ileri evre idiyopatik parkinson hastalığında nonmotor ve motor semptomlar ve fatigue skoru arasındaki ilişkinin değerlendirilmesi
Evaluation of the relationship between nonmotor and motor symptoms and fatigue score in moderate and advanced stage idiopathic parkinson's disease
OĞUZHAN DURGAN
- Mobil telefon kullanımına bağlı oluşan 900-1800 mhz radyo frekans dalgalarının meydana getirdiği elektromanyetik alanın iliak kanat kemik mineral yoğunluğuna etkisi
The effect of electromagnetic fields on bone mineral density of iliac bone produced by 900-1800 mhz radio frequency waves dependent on cellular phone usage
BEŞİR ANDAÇ AKSOY
Tıpta Uzmanlık
Türkçe
2006
Ortopedi ve TravmatolojiSüleyman Demirel ÜniversitesiOrtopedi ve Travmatoloji Ana Bilim Dalı
PROF.DR. NEVRES HÜRRİYET AYDOĞAN
- Parkinson hastalığında uygulanan derin beyin stimülasyonu tedavisinin Türkiye'deki dört farklı merkezdeki maliyet etkinlik ve yararlılık analizi
The cost benefit and effectiveness anlayze of dbs therapy on parkinson's disease in four different university hospitals in Turkey
YAKUP ÖZSEZER
Doktora
Türkçe
2020
Sağlık Kurumları Yönetimiİstanbul Okan ÜniversitesiSağlık Yönetimi Ana Bilim Dalı
DR. ÖĞR. ÜYESİ YILDIRIM BEYAZIT GÜLHAN